PolyPeptide Group (PPGN.SW) Osake Kurssi
PolyPeptide Group Kurssi
Liikevaihto on kasvanut 11,4 % vuodessa viimeisten 7 vuoden aikana 351,35 M EUR:een. Osakekohtainen tulos on laskenut 25,0 % vuodessa viimeisten 4 vuoden aikana. PolyPeptide Groupn nettomarginaali on nyt −5,7 %, laskenut 16,9 %:sta muutama vuosi sitten. PolyPeptide Groupn osinkotuotto on tällä hetkellä noin 0,68 %. Jakosuhde on noin 139 % tuloksesta. Analyytikoiden mediaanitavoitehinta on 40,56 EUR, eli ali nykyhintaa 8,1 %. 13 analyytikosta 11 suosittaa ostoa — kokonaiskonsensus on Osta.
PolyPeptide Group osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
PolyPeptide Group liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset PolyPeptide Group -osakkeesta
The business model of PolyPeptide Group AG, a leading contract manufacturing organization, focuses on producing custom-made peptides and peptide-based drugs for pharmaceutical companies worldwide. With over 60 years of expertise, PolyPeptide offers a comprehensive range of integrated services, including peptide synthesis, manufacturing, and analytical development. By leveraging their state-of-the-art facilities and cutting-edge technologies, the company ensures high-quality standards and regulatory compliance. PolyPeptide's skilled team collaborates closely with clients at every stage of the development process, from research and development to commercial production. Through their dedication to innovation and customer satisfaction, PolyPeptide Group AG strives to be the preferred partner for peptide-based therapeutic solutions.
PolyPeptide Group AG is primarily active in the pharmaceutical industry.
The main competitors of PolyPeptide Group AG in the market include companies such as Bachem Holding AG, Lonza Group Ltd., and CordenPharma International.
PolyPeptide Group AG is a renowned company engaged in the development and manufacturing of peptide-based drugs. Established in [year], PolyPeptide Group AG has emerged as a global leader in this field. With its cutting-edge research and development capabilities, the company has successfully catered to diverse industries, including pharmaceuticals, biotechnology, and cosmetics. PolyPeptide Group AG's commitment to excellence, innovation, and customer satisfaction has helped it forge strong partnerships with leading companies worldwide. Leveraging its extensive expertise, PolyPeptide Group AG continues to revolutionize the peptide industry, driving advancements in therapeutics and creating a meaningful impact on patients' lives globally.
PolyPeptide Group AG has achieved several significant milestones. To begin with, the company successfully expanded its global reach by establishing state-of-the-art production facilities in India and Sweden. Additionally, PolyPeptide Group AG has consistently delivered high-quality peptide-based solutions for pharmaceutical and biotech companies worldwide. The company also received regulatory approvals for several innovative peptide therapeutics, further strengthening its position in the market. Furthermore, PolyPeptide Group AG has collaborated with renowned industry leaders, facilitating the development of cutting-edge therapies. Overall, the company's commitment to innovation, global expansion, and strategic partnerships has led to its remarkable achievements in the field of peptide-based solutions.
PolyPeptide Group AG is primarily present in multiple countries and regions worldwide, ensuring a global reach for its operations. This Swiss-based company has established a strong presence in Europe, with facilities in Belgium, France, Sweden, and Switzerland. Additionally, PolyPeptide Group AG operates in the United States, with manufacturing facilities in California and Scandinavia. The company's broad geographical presence allows it to cater to a diverse client base and strengthen its position as a leading provider of peptide-based solutions in the pharmaceutical and biotech industries.
PolyPeptide Group AG represents a strong commitment to excellence and innovation in the pharmaceutical industry. With a focus on peptide manufacturing, the company strives to deliver high-quality products and services to its customers. PolyPeptide Group AG values scientific expertise, customer satisfaction, and compliance with regulatory standards. Their corporate philosophy emphasizes collaboration, integrity, and sustainable practices. Through their cutting-edge research and development, the company aims to contribute to the advancement of healthcare. By consistently delivering innovative peptide solutions, PolyPeptide Group AG has established itself as a trusted leader in the industry.
Analyytikot asettavat tällä hetkellä PolyPeptide Group-osakkeelle keskimääräisen tavoitehinnan 40,32 EUR (mediaani: 40,56 EUR), mikä merkitsee −8,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 13 analyytikkoarvioon.
13 analyytikkoa arvioi tällä hetkellä PolyPeptide Group-osaketta: 11 suosittaa ostoa, 1 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat PolyPeptide Group-yhtiöltä 500,23 M EUR liikevaihtoa ja 0,86 EUR osakekohtaista tulosta.
PolyPeptide Group-osake (PPGN.SW) on listattuna 3 pörssissä, muun muassa: London (0AAJ.L), SIX (Zürich) (PPGN.SW).
The PolyPeptide Group AG is an internationally active company based in Switzerland. Founded in 1952, it specializes in the production of peptides and proteins for the pharmaceutical industry. PolyPeptide's business model is based on the production and marketing of pharmaceutical peptides and proteins for clinical applications and research. The company offers its customers a wide range of products and services, including: - Synthetic production of peptides and proteins for the pharmaceutical industry. - Research services for the development of peptide-based drugs and diagnostics. - Custom manufacturing of peptides and proteins for research and development. - Production of therapeutic peptides and proteins for clinical applications. To provide these services, PolyPeptide operates production facilities in Sweden, France, India, and the United States. These locations allow the company to quickly respond to the needs of its customers and offer the best solutions for their specific requirements. PolyPeptide's divisions can be described as follows: - Pharmaceutical Peptides: PolyPeptide produces pharmaceutical peptides for clinical applications. This includes drugs for the treatment of cancer, diabetes, autoimmune diseases, and infectious diseases. - Research Peptides: PolyPeptide supplies peptides for research and development of drugs and diagnostics. These peptides allow the research community to gain new insights into molecular processes in the body. - Custom Peptides: The company manufactures custom peptides for research and development. This service is aimed at customers in science and industry who need tailored peptides for their specific applications. - Manufacturing of Therapeutic Proteins: PolyPeptide is a leading provider of therapeutic proteins and peptides for the pharmaceutical industry. This includes drugs for the treatment of cancer, neurological disorders, and metabolic diseases. PolyPeptide focuses on developing innovative peptides and proteins for the pharmaceutical industry. Through continuous research and development and collaboration with industry customers, the company is able to offer its customers the latest products and services. In addition, PolyPeptide emphasizes quality and reliability. All products are manufactured according to the highest quality standards and undergo strict controls. This gives customers the assurance that they will always receive products of the highest quality. Conclusion: The PolyPeptide Group AG is a leading provider of peptides and proteins for the pharmaceutical industry. With its wide range of products and its focus on innovation, quality, and reliability, PolyPeptide is a trusted partner for its customers in the industry and the scientific community.
odotettu liikevaihto PolyPeptide Group on 500,23 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto PolyPeptide Group on 28,23 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
PolyPeptide Group:n hinta-voitto-suhde (P/E) on tällä hetkellä 51,58. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan PolyPeptide Group-osakkeen arvostusta.
PolyPeptide Group:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,91. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii PolyPeptide Group-osakkeen arvostuskennuslukuna.
PolyPeptide Group:n Eulpool-laatuscore on 4/10.
PolyPeptide Group:n ISIN on CH1110760852. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
PolyPeptide Group:n ticker on PPGN.SW. Tämä pörssinoteeraus käytetään PolyPeptide Group-osakkeiden kauppaan pörssissä.
PolyPeptide Group osake
PolyPeptide Group vertaisryhmä
PolyPeptide Group Ticker
PolyPeptide Group FIGI
Kaikki tunnusluvut ja syvällinen analyysi PolyPeptide Group:sta
Meidän osakeanalyysimme PolyPeptide Group-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut PolyPeptide Group:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: